New Commercial Model to Improve ROI
Outsourced healthcare services provider Ashfield, part of UDG Healthcare, has announced the launch of an agile, multi-channel engagement model underpinned by a field analytics engine to address the challenges of pharmaceutical companies needing to maintain or improve return on investment (ROI). Utilizing the AshfieldGuide, a sales analytics and planning platform, The Ashfield Solution is said to provide a more efficient, impactful and agile sales model with the capability to flex resources in "real-time" in reaction to market events.
The new model helps pharmaceutical companies optimize their investment in light of margin pressure, loss of exclusivity, new product data and new market entrants including biosimilars. It reportedly provides advanced analytics capabilities in response to curve modeling, segmentation techniques, mix modeling and geospatial optimization. In addition, the commercial model delivers engagement optimization and monthly reporting on ROI, call attainment and performance.
For more information, visit www.ashfieldhealthcare.com
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
